David J. Woodhouse's Insider Trades & SAST Disclosures
David J. Woodhouse's most recent trade in Surrozen Inc was a trade of 1,333 Option (right to buy) done . Disclosure was reported to the exchange on June 5, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David J. Woodhouse.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 1,333 | 1,333 | - | - | Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 450,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 400,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 381,600 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 255,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | 05 Apr 2024 | 97,654 | 0 (0%) | 0% | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 95,400 | 0 | - | - | Restricted Stock Unit | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 87,013 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 57,833 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | 05 Apr 2024 | 23,993 | 0 (0%) | 0% | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | David Woodhouse J. | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 16 Jan 2024 | 13,032 | 131,822 (0%) | 0% | 1.3 | 17,463 | Common Stock |
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 20,000 | 20,000 | - | - | Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 381,600 | 381,600 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 127,200 | 144,854 (0%) | 0% | 0 | Common Stock | |
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 20,000 | 20,000 | - | - | Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.70 per share. | 29 Dec 2021 | 12,987 | 12,987 (0%) | 0% | 7.7 | 100,000 | Common Stock |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2021 | 12,987 | 87,013 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2021 | 4,667 | 57,833 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.14 per share. | 29 Dec 2021 | 4,667 | 17,654 (0%) | 0% | 8.1 | 37,989 | Common Stock |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges